Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Year: 2022
Type: article
Abstract: Timely and accurate diagnosis of Alzheimer's disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.
Authors: Davide Angioni, J. Delrieu, O. Hansson, H. Fillit, P. Aisen, J. Cummings, J.R. Sims, J.B. Braunstein, M. Sabbagh, T. Bittner, M. Pontecorvo, S. Bozeat, J.L. Dage, E. Largent, S. Mattke, O. Correa, L.M. Gutierrez Robledo, V. Baldivieso, D.R. Willis, A. Atri, R.J. Bateman, P.-J. Ousset, B. Vellas, M. Weiner
Institutions: Centre Hospitalier Universitaire de Toulouse, Skåne University Hospital, Alzheimer's Drug Discovery Foundation, University of Southern California, University of Nevada, Las Vegas, Eli Lilly (United States), C2N Diagnostics (United States), Barrow Neurological Institute, Roche (Switzerland), Indiana University Indianapolis, Indiana University School of Medicine, University of Pennsylvania, AdventHealth, Brigham and Women's Hospital, Harvard University, Banner Health, Banner Sun Health Research Institute, Washington University in St. Louis, University of New Mexico, University of New Mexico Health Sciences Center, University of California, San Francisco
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
Awards: G1598070753, G2622865600, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC), G492415912, Arizona Alzheimer's Disease Core Center, Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission, Arizona Alzheimer's Disease Research Center, Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative
OpenAlex ID: W4307342071